The submission of an IND to the FDA is a positive step forward in the drug development process, indicating progress in Aurinia's pipeline. If the FDA approves the application, it allows the company to proceed with clinical trials, which is a critical milestone. This news is likely to be viewed positively by investors, as it demonstrates advancement in the company's research and development efforts. However, the impact is not at the highest level of importance since the drug is still in early stages and actual market approval, if granted, would be several years away.